(Q43477729)

23 November 2017

title

Interpreting MYC and BCL2 in diffuse large B-cell lymphoma (English)

1 reference

23 November 2017

Catherine Lai

1

1 reference

23 November 2017

Cliona Grant

series ordinal

2

1 reference

23 November 2017

Kieron Dunleavy

series ordinal

3

1 reference

23 November 2017

language of work or name

1 reference

1 October 2013

1 reference

23 November 2017

1 reference

23 November 2017

volume

54

1 reference

23 November 2017

issue

10

1 reference

23 November 2017

page(s)

2091-2092

1 reference

Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.806803

Non-transcriptional control of DNA replication by c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.806803

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.806803

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.806803

MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.806803

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.806803

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.806803

10.3109/10428194.2013.806803

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference